All nine proposals approved at NewAmsterdam Pharma 2025 AGM

NewAmsterdam Pharma Co N.V.

Quorum of 83.6M ordinary shares (74.45%) voted; all nine agenda items passed.
Dutch statutory annual accounts for FY2024 approved: 83.5M for, 5.6K against.
Three non-executive directors (Joustra, McKenna, Gulfo) each elected with >79M for votes.
Michael Davidson reappointed executive director (70.5M for, 9.2M against); James Topper reappointed non-executive.
Share buyback authorization extended (71.4M for, 12.2M against); say-on-pay approved and set for annual frequency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.